Abstract
Knockout of the ORF8 protein has repeatedly spread through the global viral population during SARS-CoV-2 evolution. Here we use both regional and global pathogen sequencing to explore the selection pressures underlying its loss. In Washington State, we identified transmission clusters with ORF8 knockout throughout SARS-CoV-2 evolution, not just on novel, high fitness viral backbones. Indeed, ORF8 is truncated more frequently and knockouts circulate for longer than for any other gene. Using a global phylogeny, we find evidence of positive selection to explain this phenomenon: nonsense mutations resulting in shortened protein products occur more frequently and are associated with faster clade growth rates than synonymous mutations in ORF8. Loss of ORF8 is also associated with reduced clinical severity, highlighting the diverse clinical impacts of SARS-CoV-2 evolution.
Competing Interest Statement
ALG reports contract testing from Abbott, Cepheid, Novavax, Pfizer, Janssen and Hologic, research support from Gilead, salary and stock grants for an immediate family member, outside of the described work. All other authors declare no competing interests.
Funding Statement
CW is funded by Achievement Rewards for College Scientists. TB is an Investigator of the Howard Hughes Medical Institute. MF is supported by the NSF Graduate Research Fellowship Program under Grant No. DGE-1762114. The Scientific Computing Infrastructure at Fred Hutch is supported by NIH grants S10-OD-020069 and S10-OD-028685. Funding for Washington Department of Health data collection was provided by Centers for Disease Control and Prevention (CDC) ELC EDE.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of Washington State waived ethical approval for this work under Washington State IRB Exempt Determination 2020-102.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All GISAID metadata and sequences used in analyses are available at gisaid.org/EPI_SET_230921by. The SARS-CoV-2 UShER phylogeny used in this study was downloaded on May 1, 2023 from http://hgdownload.soe.ucsc.edu/goldenPath/wuhCor1/UShER_SARS-CoV-2/. Clinical data from the Washington Disease Reporting System is not shared due to patient confidentiality. All code used in this analysis is available at: https://github.com/blab/ncov-orf8.
https://www.epicov.org/epi3/epi_set/EPI_SET_230921by?main=true
